黑色素瘤患者中免疫检查点抑制剂相关神经免疫不良事件的发生率与结局
该回顾性分析纳入2015年1月1日至2022年4月20日在Ella免疫肿瘤与黑色素瘤研究所接受免疫检查点抑制剂治疗的937例晚期黑色素瘤患者,8%(n=76)发生神经免疫不良事件,常见表型为肌炎(44.7%)、脑炎(10.5%)和神经病(10.5%);发生神经免疫不良事件(HR=0.4,95%CI 0.32-0.77)或任何免疫不良事件(HR=0.7195%CI 0.56-0.88)与更长生存相关。
要点
- 937例接受免疫检查点抑制剂的晚期黑色素瘤患者中8%(n=76)发生神经免疫不良事件。
- 神经免疫不良事件常见表型为肌炎44.7%、脑炎10.5%、神经病10.5%。
- 发生神经免疫不良事件(HR=0.4,95%CI 0.32-0.77)与更长生存相关。
核心结论
- 神经免疫不良事件是免疫检查点抑制剂相对常见的并发症,在本队列中占8%。
- 高龄与神经免疫不良事件的发生或严重程度无关,与非神经免疫不良事件在老年人群中发生较少形成对比。
- 再次挑战未导致危及生命的不良事件。
- 发生任何免疫不良事件与更长生存相关,该关联在神经免疫不良事件中更强。
研究设计与样本
- 对2015年1月1日至2022年4月20日在Ella免疫肿瘤与黑色素瘤研究所接受免疫检查点抑制剂治疗的晚期黑色素瘤患者进行回顾性分析。
- 免疫检查点抑制剂共给药于937例患者。
主要发现
- 至少发生一种免疫不良事件的患者占73.5%(n=689)。
- 8%(n=76)发生神经免疫不良事件,女性发病中位年龄66岁,男性68岁。
- 神经免疫不良事件后中位随访1,147天(IQR:1,091.5,范围:3,938)。
- 70岁以上患者免疫不良事件发生较少(中位数:3次事件,p=0.04,CI 2.5-4.7),而结肠炎和肺炎在18-60岁年龄组更常见(p=0.03,95%CI 0.8-0.38;p=0.009,95%CI 0.06-0.2)。
- 各年龄组中35.5%的患者出现≥3级毒性。
关键数值与推荐
- 从免疫检查点抑制剂给药至神经免疫不良事件发生的中位时间为48天,各年龄组一致。
- 神经免疫不良事件表型:肌炎44.7%、脑炎10.5%、神经病10.5%。
- 40%的患者因神经免疫不良事件需住院,46%需类固醇治疗,从神经免疫不良事件诊断至开始类固醇治疗的中位时间为4天。
- 9例患者需二线免疫抑制治疗。
- 再次挑战后71%的患者未发生额外神经免疫不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Neurologic immune-related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune checkpoint inhibitors (ICIs) of all age groups. We investigated the association between age and n-irAEs in patients treated with ICIs and examined the effect of n-irAEs on survival outcomes in a large cohort of patients with melanoma. METHODS: We conducted a retrospective analysis of patients with advanced melanoma treated with ICIs at Ella Institute for Immuno-oncology and Melanoma between January 1, 2015, and April 20, 2022. The outcomes of interest were defined as the investigation of age-related frequency and severity of n-irAEs, the need for ICI interruption, the treatment required for n-irAE management, the safety of ICI reintroduction, and n-irAE's effect on survival. RESULTS: ICI was administered to 937 patients. At least one irAE occurred in 73.5% (n = 689) of them. Among the study population, 8% (n = 76) developed a n-irAE, with a median age of 66 years in female and 68 years in male patients at onset. The median follow-up after n-irAE was 1,147 days (IQR: 1,091.5 range: 3,938). Fewer irAEs occurred in patients older than 70 years (median: 3 events, p = 0.04, CI 2.5-4.7) while specifically colitis and pneumonitis were more common in the 18-60 age group (p = 0.03, 95% CI 0.8-0.38, p = 0.009, 95% CI 0.06-0.2). Grade ≥ 3 toxicity was seen in 35.5% of patients across age groups. The median time from ICI administration to n-irAE development was 48 days across age groups. Common n-irAE phenotypes were myositis (44.7%), encephalitis (10.5%), and neuropathy (10.5%). N-irAE required hospitalization in 40% of patients and steroids treatment in 46% with a median of 4 days from n-irAE diagnosis to steroids treatment initiation. Nine patients needed second-line immunosuppressive treatment. Rechallenge did not cause additional n-irAE in 71% of patients. Developing n-irAE (HR = 0.4, 95% CI 0.32-0.77) or any irAE (HR = 0.7195% CI 0.56-0.88) was associated with longer survival. DISCUSSION: N-irAEs are a relatively common complication of ICIs (8% of our cohort). Older age was not associated with its development or severity, in contrast with non-n-irAEs which occurred less frequently in the elderly population. Rechallenge did not result in life-threatening AEs. Development of any irAEs was associated with longer survival; this association was stronger with n-irAEs.
引用
- Pepys J, Stoff R, Ramon-Gonen R, et al. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma. Neurology. 2023. PMID: 37652699. doi:10.1212/WNL.0000000000207632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。